Deletion of Interstitial Genes between TMPRSS2 and ERG Promotes Prostate Cancer Progression.
暂无分享,去创建一个
R. Bronson | K. Penney | Zhe Li | L. Mucci | Douglas E. Linn
[1] Zhe Li,et al. RUNX1, a transcription factor mutated in breast cancer, controls the fate of ER-positive mammary luminal cells , 2014, eLife.
[2] F. Brimo,et al. The prognostic role of ERG immunopositivity in prostatic acinar adenocarcinoma: a study including 454 cases and review of the literature. , 2014, Human pathology.
[3] I. Mills. Maintaining and reprogramming genomic androgen receptor activity in prostate cancer , 2014, Nature Reviews Cancer.
[4] L. Bubendorf,et al. ERG rearrangement and protein expression in the progression to castration-resistant prostate cancer , 2014, Prostate Cancer and Prostatic Disease.
[5] M. Rubin,et al. TMPRSS2:ERG gene fusion predicts subsequent detection of prostate cancer in patients with high-grade prostatic intraepithelial neoplasia. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] Jennifer R. Rider,et al. Modification of the association between obesity and lethal prostate cancer by TMPRSS2:ERG. , 2013, Journal of the National Cancer Institute.
[7] R. Cardiff,et al. ETV4 promotes metastasis in response to activation of PI3-kinase and Ras signaling in a mouse model of advanced prostate cancer , 2013, Proceedings of the National Academy of Sciences.
[8] V. Reuter,et al. TMPRSS2–ERG rearrangement in dominant anterior prostatic tumours: incidence and correlation with ERG immunohistochemistry , 2013, Histopathology.
[9] D. Zheng,et al. ETS factors reprogram the androgen receptor cistrome and prime prostate tumorigenesis in response to PTEN loss , 2013, Nature Medicine.
[10] Diane D. Liu,et al. ETS2 Mediated Tumor Suppressive Function and MET Oncogene Inhibition in Human Non–Small Cell Lung Cancer , 2013, Clinical Cancer Research.
[11] Gerald C. Chu,et al. Animal models of human prostate cancer: the consensus report of the New York meeting of the Mouse Models of Human Cancers Consortium Prostate Pathology Committee. , 2013, Cancer research.
[12] M. Loda,et al. ETV1 directs androgen metabolism and confers aggressive prostate cancer in targeted mice and patients. , 2013, Genes & development.
[13] M. Meyerson,et al. Recurrent Hemizygous Deletions in Cancers May Optimize Proliferative Potential , 2012, Science.
[14] Jennifer R. Rider,et al. The TMPRSS2:ERG Rearrangement, ERG Expression, and Prostate Cancer Outcomes: A Cohort Study and Meta-analysis , 2012, Cancer Epidemiology, Biomarkers & Prevention.
[15] Benjamin J. Raphael,et al. The Mutational Landscape of Lethal Castrate Resistant Prostate Cancer , 2012, Nature.
[16] L. Tran,et al. Pten loss and RAS/MAPK activation cooperate to promote EMT and metastasis initiated from prostate cancer stem/progenitor cells. , 2012, Cancer research.
[17] H. Schlüter,et al. ERG Status Is Unrelated to PSA Recurrence in Radically Operated Prostate Cancer in the Absence of Antihormonal Therapy , 2011, Clinical Cancer Research.
[18] T. Tsuzuki,et al. ERG gene rearrangement status in prostate cancer detected by immunohistochemistry , 2011, Virchows Archiv.
[19] J. Hicks,et al. Immunohistochemistry for ERG Expression as a Surrogate for TMPRSS2-ERG Fusion Detection in Prostatic Adenocarcinomas , 2011, The American journal of surgical pathology.
[20] L. Tran,et al. Cell autonomous role of PTEN in regulating castration-resistant prostate cancer growth. , 2011, Cancer cell.
[21] Sarat Chandarlapaty,et al. Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer. , 2011, Cancer cell.
[22] P. Jedlicka,et al. Ets2 Regulates Colonic Stem Cells and Sensitivity to Tumorigenesis , 2011, Stem cells.
[23] C. Sander,et al. Integrative genomic profiling of human prostate cancer. , 2010, Cancer cell.
[24] S. Varambally,et al. Antibody-based detection of ERG rearrangement-positive prostate cancer. , 2010, Neoplasia.
[25] Andrew R. Gehrke,et al. Genome-wide analysis of ETS-family DNA-binding in vitro and in vivo , 2010, The EMBO journal.
[26] Zhaohui S. Qin,et al. An integrated network of androgen receptor, polycomb, and TMPRSS2-ERG gene fusions in prostate cancer progression. , 2010, Cancer cell.
[27] Markus Reischl,et al. ERG rearrangement is specific to prostate cancer and does not occur in any other common tumor , 2010, Modern Pathology.
[28] A. Malek,et al. ETS Transcription Factors Control Transcription of EZH2 and Epigenetic Silencing of the Tumor Suppressor Gene Nkx3.1 in Prostate Cancer , 2010, PloS one.
[29] O. Witte,et al. Isolation, cultivation and characterization of adult murine prostate stem cells , 2010, Nature Protocols.
[30] W. Linehan,et al. Inhibition of Tumor Cell Motility by the Interferon-inducible GTPase MxA* , 2009, Journal of Biological Chemistry.
[31] W. Gerald,et al. TMPRSS2-ERG gene fusion is not associated with outcome in patients treated by prostatectomy. , 2009, Cancer research.
[32] T. Golub,et al. Estrogen-dependent signaling in a molecularly distinct subclass of aggressive prostate cancer. , 2008, Journal of the National Cancer Institute.
[33] R. Shah,et al. Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer. , 2008, Cancer research.
[34] M. Teixeira,et al. Chromosome mechanisms giving rise to the TMPRSS2-ERG fusion oncogene in prostate cancer and HGPIN lesions. , 2008, The American journal of surgical pathology.
[35] J Cuzick,et al. Duplication of the fusion of TMPRSS2 to ERG sequences identifies fatal human prostate cancer , 2008, Oncogene.
[36] G. Jenster,et al. TMPRSS2:ERG fusion by translocation or interstitial deletion is highly relevant in androgen-dependent prostate cancer, but is bypassed in late-stage androgen receptor-negative prostate cancer. , 2006, Cancer research.
[37] J. Tchinda,et al. TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. , 2006, Cancer research.
[38] A. Evans,et al. Three-color FISH analysis of TMPRSS2/ERG fusions in prostate cancer indicates that genomic microdeletion of chromosome 21 is associated with rearrangement. , 2006, Neoplasia.
[39] Lynette M. Smith,et al. N‐cadherin switching occurs in high Gleason grade prostate cancer , 2006, The Prostate.
[40] M. Bustin,et al. Chromosomal protein HMGN1 modulates the expression of N‐cadherin , 2005, The FEBS journal.
[41] J. Tchinda,et al. Recurrent Fusion of TMPRSS2 and ETS Transcription Factor Genes in Prostate Cancer , 2005, Science.
[42] W. Muller,et al. Ets2-dependent microenvironmental support of mouse mammary tumors , 2005, Oncogene.
[43] Pablo Tamayo,et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[44] Jose J. Galvez,et al. Prostatic intraepithelial neoplasia in genetically engineered mice. , 2002, The American journal of pathology.
[45] C. Hauser,et al. Altered Ets transcription factor activity in prostate tumor cells inhibits anchorage-independent growth, survival, and invasiveness , 2000, Oncogene.
[46] Inge Jonassen,et al. ERG upregulation and related ETS transcription factors in prostate cancer. , 2007, International journal of oncology.